Schedule II stimulant products used in 2020
| Prescriptions | Persons | |
| No (%) | No (%)* | |
| Drug name | ||
| Amphetamine products | ||
| Amphetamine and combinations | 1 429 450 (64.8) | 183 019 (66.3) |
| Lisdexamfetamine | 452 415 (20.5) | 66 844 (24.2) |
| Dextroamphetamine | 26 681 (1.2) | 4 243 (1.5) |
| Methamphetamine† | 211 (<0.1) | 44 (<0.1) |
| Methylphenidate products | ||
| Methylphenidate | 262 191 (11.9) | 42 089 (15.2) |
| Dexmethylphenidate | 36 645 (1.7) | 6 446 (2.3) |
Source: MarketScan Research Databases, 2019–2020, commercially insured adults, age 19–64 years. Schedule II stimulants include amphetamine and methylphenidate drug products.
*Per cent totals by person do not add to 100 due to patients taking multiple stimulants.
†Prescription drug product only (excludes illicit street drugs).